Crohn’s Disease News and Research

RSS

CCFA announces $17.5 million grant to establish Crohn's disease, ulcerative colitis research platform

The Crohn's & Colitis Foundation of America announces a three-year, $17.5 million grant from The Leona M. and Harry B. Helmsley Charitable Trust to establish an integrated knowledge platform designed to centralize and aggregate patient information - with linked biosamples - across multiple research efforts.

15 May 2015

Bacterial imbalance in the gut can lead to inflammation similar to Crohn's disease

Crohn's disease is one of a family of chronic inflammatory bowel diseases (IBD). While it has already been proven to have genetic causes, scientists have now shown that the presence of certain intestinal bacteria also plays a role.

24 Apr 2015

Raja Atreya wins award for novel diagnostic method to predict treatment outcomes in Crohn's disease

Professor Raja Atreya from Medical Clinic 1 of the Erlangen University Hospital has won the 60,000€ Paul Ehrlich and Ludwig Darmstaedter Prize for Young Researchers for 2015. With his innovative diagnostic method, physicians can predict the clinical response of an expensive treatment of Crohn's disease which is associated with potential side effects.

17 Mar 2015

Study finds racial disparities among children with Crohn's disease

A study published recently in the IBD Journal found significant differences in hospital readmissions, medication usage, and both medical and surgical complications of children with Crohn's disease related to race. In the study, black children had a 1.5 times higher frequency of hospital readmissions because of Crohn's disease compared to white children.

28 Feb 2015

TNF signaling molecule triggers Crohn's disease, ulcerative colitis

Cells lining the intestinal tract form a critical barrier, protecting our bodies from the billions of bacteria living in the gut. Breaches in this barrier are driven largely by a single signaling molecule called tumor necrosis factor (TNF), elevated amounts of which are associated with inflammatory bowel diseases like Crohn's disease and ulcerative colitis.

17 Feb 2015

Findings may lead to novel therapeutic approaches to prevent fibrosis in Crohn's disease patients

A natural protein made by immune cells may limit fibrosis and scarring in colitis, according to research published in the inaugural issue of Cellular and Molecular Gastroenterology and Hepatology, the new basic science journal of the American Gastroenterological Association.

16 Jan 2015

British scientists take major initiative to tackle Crohn's disease

British scientists are playing a key role in a global quest to find the causes of an incurable bowel condition.

15 Jan 2015

$TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease$

TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has enrolled the first patient in its phase IIb clinical trial of its lead product Ovasave in refractory Crohn’s disease.

4 Dec 2014

Genetic changes in patients with Crohn's disease could hold clues to fighting illness

Genetic changes that occur in patients with the bowel condition Crohn's disease could hold clues to fighting the illness.

27 Aug 2014

Study finds a host of new clues on gene-environment interactions in Crohn's disease

A new study finds a wide range of epigenetic changes-alterations in DNA across the genome that may be related to key environmental exposures-in children with Crohn's disease (CD), reports Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America.

23 Aug 2014

Findings may lead to better ways for preventing gum disease, diabetes and Crohn's disease

Bacteria inside your mouth drastically change how they act when you're diseased, according to research using supercomputers at the Texas Advanced Computing Center.

13 Aug 2014

Showers and rivers may play role in the development of Crohn's disease

Humans may be exposed to bacteria linked with Crohn's disease through fine spray from showers and rivers according to research led by Lancaster University.

24 Jul 2014

Treating ulcerative colitis and Crohn’s disease

Ulcerative colitis and Crohn’s disease are idiopathic (we don’t know the cause) inflammatory diseases (IBD) of the colon and/or small bowel. They are chronic in that we do not have a medical cure and are differentiated from IBS (irritable bowel syndrome) by inflammation that causes ulcerations of the GI tract.

7 Jul 2014

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

28 May 2014

Gastroenterologists select efficacy over safety, tolerability when prescribing new drug for Crohn's disease

Decision Resources Group finds that, when asked to indicate the relative importance of product attributes when prescribing a new drug for Crohn's disease (CD), the highest percentages of surveyed gastroenterologists in the United States and Europe selected efficacy over safety and tolerability or delivery.

22 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

New study shows increase in certain macrophages may lead to therapeutic targets for Crohn's disease

For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease.

4 Mar 2014

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF-α agents, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

3 Feb 2014

Subset of TH17 cells linked to inflammation in Crohn’s disease patients, find TSRI scientists

Two-thirds to three-quarters of the estimated 700,000 Americans living with Crohn’s disease, an autoimmune condition that can disrupt the entire gastrointestinal tract, will require surgery at some point during their life. Patients and physicians often turn to this surgical intervention after a patient develops resistance to current treatments, such as steroids.

9 Jan 2014